NCT07017426View on ClinicalTrials.gov

Fuzheng Huayu Tablets Reduce the Occurrence of Re-Decompensation Events in Patients With First Decompensation of Hepatitis B-Related Liver Cirrhosis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study

NANot yet recruitingINTERVENTIONAL

Enrollment

432

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

July 1, 2027

Study Completion Date

July 1, 2027

Conditions

Decompensated Hepatitis B Cirrhosis

Interventions

DRUG

Fuzheng Huayu tablets

Fuzheng Huayu Tablets are composed of various medicinal ingredients such as Salvia miltiorrhiza, Prunus persica seed, Gynostemma pentaphyllum, pine pollen, Cordyceps sinensis, and Schisandra chinensis. They have the functions of promoting blood circulation and removing blood stasis, nourishing the liver and enriching essence, and can be used to treat chronic liver diseases, anti-fibrosis, and patients with liver cirrhosis.

OTHER

Placebo Comparator

placebo combined with conventional antiviral therapy

All Listed Sponsors

lead

Zhiyun Yang

OTHER

NCT07017426 - Fuzheng Huayu Tablets Reduce the Occurrence of Re-Decompensation Events in Patients With First Decompensation of Hepatitis B-Related Liver Cirrhosis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study | Biotech Hunter | Biotech Hunter